Document is current
Any future updates will be listed below
-
Authors
Nishiwaki, Satoshi https://orcid.org/0000-0002-6430-8958
Terakura, Seitaro
Morishita, Takanobu
Goto, Tatsunori
Inagaki, Yuichiro
Miyao, Kotaro
Fukushima, Nobuaki
Hirano, Daiki
Tange, Naoyuki
Kurahashi, Shingo
Kuwatsuka, Yachiyo
Kasai, Masanobu
Iida, Hiroatsu
Ozeki, Kazutaka
Sawa, Masashi
Nishida, Tetsuya
Kiyoi, Hitoshi
-
Funding
Funding for this research was provided by:
Aichi Cancer Research Foundation
Japanese Society of Hematology Research Grant
- License Information
-
More Information
Article History
Received: 18 November 2024
Revised: 7 January 2025
Accepted: 8 January 2025
First Online: 17 January 2025
Declarations
:
: S.N. received honoraria from Otsuka Pharmaceutical Co. Ltd. K.M. received honoraria from Janssen Pharmaceutical K.K., Sanofi K.K., Ono Pharmaceutical Co. Ltd., Bristol-Myers Squibb K.K., Abbvie GK, Genmab A/S, Kyowa Kirin Co. Ltd., Chugai Pharmaceutical Co. Ltd., Nippon Shinyaku Co. Ltd., AstraZeneca plc., Eisai Co. Ltd., Asahi Kasei Co., Takeda Pharmaceutical Co. Ltd., Astellas Pharma Inc., PharmaEssentia Co. and JCR Pharmaceuticals Co. Ltd. H.I. received research funding from Chugai Pharmaceutical Co. Ltd. and Nippon Kayaku Co. Ltd., and honoraria from Astellas Pharma Inc., Novartis Pharma K.K., Abbvie Inc., Janssen Pharmaceutical K.K., Chugai Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. and Sanofi K.K. M.S. received honoraria from Kyowa Kirin Co. Ltd., Chugai Pharmaceutical Co. Ltd., Pfizer Inc., Astellas Pharma Inc., Nippon Shinyaku Co. Ltd., Ono Pharmaceutical Co. Ltd., MSD, Bristol-Myers-Squibb K.K., Asahi-Kasei Pharma Co., Novartis Pharma K.K., Eisai Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Sumitomo Pharma Co. Ltd., Sanofi K.K., Takeda Pharmaceutical Co. Ltd., Celgene Co., Mochida Pharmaceutical Co. Ltd., Shire plc, Mundipharma K.K., Abbvie Inc., CSL Behring, SymBio Pharmaceuticals, Janssen Pharmaceutical K.K., AstraZeneca plc, Daiichi Sankyo Co. Ltd., and GlaxoSmithKline plc. H.K. received research funding from Chugai Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Zenyaku Kogyo Co. Ltd., Sumitomo Pharma Co. Ltd., Eisai Co. Ltd., Daiichi Sankyo Co. Ltd., Otsuka Pharmaceutical Co., Ltd., Perseus Proteomics Inc., CURED Co. Ltd., Astellas Pharma Inc., Asahi Kasei Co., Abbvie Inc., Nippon Shinyaku, Co. Ltd., JCR Pharmaceuticals Co. Ltd., and Takeda Pharmaceutical Co. Ltd., and honoraria from Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Daiichi Sankyo Co., Ltd., Astellas Pharma Inc., Abbvie Inc., Nippon Shinyaku Co., Ltd., AstraZeneca plc., Novartis Pharma KK., SymBio Pharmaceuticals Ltd.., Bristol-Myers Squibb K.K., Amgen Inc., Meiji Seika Pharma Co. Ltd., Pfizer Inc., Nippon Kayaku Co. Ltd., and Towa Pharmaceutical Co. Ltd. outside of this study. The remaining authors declare no competing financial interests.
